Ascendis Pharma: Cantor Fitzgerald maintains Overweight, PT raised to $203.

Ascendis Pharma: Cantor Fitzgerald maintains Overweight, PT raised to $203.

Ascendis Pharma A/S (Nasdaq: ASND) reported robust financial results for the second quarter of 2025, with revenue growth driven by the continued uptake of YORVIPATH® and SKYTROFA®. The company's President and Chief Executive Officer, Jan Mikkelsen, highlighted the significant milestones achieved and the potential for future growth.

Key Financial Highlights

- Revenue: Total revenue for the second quarter of 2025 was €158.0 million, a year-over-year increase of 397.8% compared to €36.0 million in the same period in 2024. Commercial product revenue grew to €97.8 million, reflecting a strong performance from YORVIPATH®.
- Product Revenue: YORVIPATH® revenue totaled €103.0 million, while SKYTROFA® revenue was €50.7 million. Both products experienced a negative foreign currency impact compared to the previous quarter.
- Operating Expenses: Total operating expenses for the second quarter of 2025 were €179.5 million, up from €157.8 million in the same period in 2024. This increase was primarily due to commercial expansion activities.
- Net Loss: Ascendis Pharma reported a net loss of €38.9 million for the second quarter of 2025, compared to a net loss of €109.4 million in the same period in 2024.

Clinical Milestones

Ascendis Pharma made significant strides in its clinical programs:

- YORVIPATH®: The company initiated PaTHway60, a single-arm safety and efficacy trial to support a U.S. label expansion for YORVIPATH®.
- SKYTROFA®: SKYTROFA® was approved by the FDA for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD).
- TransCon CNP: The New Drug Application (NDA) for the treatment of children with achondroplasia was accepted by the FDA under Priority Review, with a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2025. The company also plans to submit an IND or similar to investigate TransCon CNP alone and in combination with TransCon hGH for the treatment of hypochondroplasia.

Investment Outlook

Cantor Fitzgerald recently maintained an Overweight rating on Ascendis Pharma with a price target of $203, reflecting the company's strong Q2 2025 results and the potential for future growth. The analyst noted that Ascendis Pharma's innovative TransCon technology platform and its pipeline of high-value medicines position it well to address unmet medical needs in endocrine rare diseases and other large indications.

Conclusion

Ascendis Pharma's Q2 2025 results demonstrate the company's ability to drive revenue growth and achieve significant clinical milestones. With a strong pipeline and a focus on addressing unmet medical needs, Ascendis Pharma is well-positioned to continue its growth trajectory.

References

[1] https://www.biospace.com/press-releases/ascendis-pharma-reports-second-quarter-2025-financial-results